• Foretinib: Separating Growth Arrest From Cell Death

  2026-08-14

  Foretinib (GSK1363089) is a multikinase inhibitor whose effects can reflect both cytostatic growth arrest and cell killing. This guide combines its Met and VEGFR pharmacology with a quantitative assay framework for interpreting viability, motility, invasion, and metastasis data.

• Anlotinib Hydrochloride: From Assay to Tumor Biology

  2026-08-14

  Anlotinib hydrochloride connects nanomolar kinase inhibition with measurable angiogenic phenotypes and a cautiously interpreted rare-tumor case. This article explains how to translate receptor, endothelial, pharmacokinetic, and clinical evidence into better cancer research decisions.

• NMDA in Retinal Excitotoxicity Research

  2026-08-13

  NMDA (N-Methyl-D-aspartic acid) provides a direct, controllable way to model receptor-driven calcium stress in retinal and neuronal systems. This workflow connects excitotoxic injury with oxidative stress, ferroptosis readouts, and BMP4-GPX4 neuroprotection experiments.

• From TIL Biology to Better Fluorescence Readouts

  2026-08-13

  A translational perspective on how tumor-microenvironment modulation can improve TIL therapy—and how disciplined fluorescence workflows, including the FITC Goat Anti-Mouse IgG (H+L) Antibody, help convert mechanistic hypotheses into reproducible evidence.

• Anlotinib Hydrochloride: Reliable Assay Workflows

  2026-08-12

  This scenario-based guide explains how Anlotinib hydrochloride supports reproducible endothelial migration, tube-formation, viability, and signaling studies. It connects quantitative product data with practical assay design and outlines when SKU C8688 is a sensible research-use choice.

• GDC-0941 for PI3K/Akt Pathway Assays

  2026-08-12

  GDC-0941 provides a practical way to connect PI3K signaling changes with cancer cell proliferation, apoptosis, and therapy resistance. This workflow translates PI3K/Akt biology into reproducible cell-based assays, including models of trastuzumab-resistant HER2-amplified cancer and liver cancer stem cell phenotypes.

• CTCF, Centromere Function, and Mitotic Fidelity

  2026-08-11

  The reference study uses rapid auxin-inducible degradation to show that CTCF is required for centromere performance, accurate mitosis, and normal post-mitotic nuclear shape. Its experiments distinguish a centromere-maintenance defect from impaired CENP-E recruitment, providing a mechanistic framework for studying chromosome alignment regulation.

• P2RX1-Driven Mitochondrial Apoptosis in Ph+ ALL

  2026-08-11

  Li et al. identify P2RX1 as a regulator of tyrosine kinase inhibitor response in Philadelphia chromosome-positive acute lymphoblastic leukemia, linking purinergic signaling to calcium imbalance, CaMKII activation, PI3K/Akt suppression, and mitochondrial apoptosis. The findings provide a mechanistic framework for studying treatment sensitivity while highlighting the need for validation in primary leukemia models and in vivo systems.

• Cy5 Hydrazide for Carbonyl Labeling Workflows

  2026-08-10

  Cy5 hydrazide enables far-red detection of aldehyde- and ketone-bearing biomolecules in protein, glycoprotein, oligonucleotide, and nanoparticle workflows. Its strongest differentiator is sensitive carbonyl readout without requiring a sulfonated dye, provided the low-solubility reagent is handled with an appropriate DMSO-based preparation and cleanup strategy.

• Glutamine Metabolism in Hepatic Stellate Cells

  2026-08-09

  The 2022 Cell Death and Disease study identifies SIRT4-mediated control of glutamate dehydrogenase as a metabolic brake on hepatic stellate cell activation and liver fibrosis. Its combination of pharmacological, genetic, cellular, and in vivo evidence supports glutamine catabolism as a mechanistically grounded target for antifibrotic research.

• IWR-1-endo: From Pathway Blockade to Cell States

  2026-08-08

  IWR-1-endo is a potent Wnt signaling inhibitor for dissecting β-catenin-dependent biology. This article connects its Axin-complex mechanism with cell-state-resolved assay design inspired by large-scale single-nucleus profiling in atrial fibrillation research.

• Toremifene in Breast Cancer: 20 Years of Evidence

  2026-08-07

  This review synthesizes two decades of clinical and pharmacologic evidence on toremifene, positioning it as an effective endocrine option for selected postmenopausal patients with hormone-sensitive breast cancer. Its main contribution is a clinically useful comparison of toremifene with tamoxifen and aromatase inhibitors, while highlighting receptor biology, CYP2D6-related metabolism, bone effects, lipid effects, and treatment tolerability.

• Prochlorperazine as a Dopamine D2 Receptor Antagonist in Res

  2026-08-07

  Prochlorperazine’s multi-receptor antagonism and robust in vitro efficacy make it a versatile tool for melanoma research and antiemetic assay development. Recent clinical trials underscore its translational potential, opening new avenues for both mechanistic studies and applied workflows.

• SMYD2 Inhibition Prevents Cisplatin-Induced Renal Fibrosis

  2026-08-06

  The referenced study demonstrates that pharmacological inhibition of SMYD2 with agents such as LLY-507 protects against cisplatin-induced renal fibrosis and inflammation in preclinical models. This work identifies SMYD2 as a regulator of chronic kidney disease progression, highlighting new avenues for targeted epigenetic therapy.

• Tat-Induced H3K27me3 and EZH2 Drive HIV Latency in Astrocyte

  2026-08-06

  This study demonstrates that HIV-1 Tat expression promotes histone H3K27 trimethylation via upregulation of EZH2 and MeCP2, thereby contributing to the establishment and maintenance of HIV latency in astrocytes. Pharmacological inhibition of EZH2 with GSK126 reactivates latent HIV, providing mechanistic insight and a potential epigenetic intervention point.

7769 records 2/518 page Previous Next 12345 下5页 Last page